Chairman and Medical Director
Excel Diagnostics and Nuclear Oncology Center
Considering the curent vigorous evaluation of new PET radiopharmaceuticals by FDA, whcih is one of the federal Government agencies like CMS, these agencies need to communicate and collaborate together and immediate coverage should be issued at the Federal level (Not local CMS contractors)for all FDA approved PET radiotracers. If CMS has anything to add to the current vigorous requirements of the FDA , they can do that so at the end of the process "FDA approval be equal to CMS coverage". In this way Government can save significnat amount of time, money and prevent frustrative administrative delay! Also, the language should cover ALL other FDA approved positron emitters such as Ga-68, Cu-64, Y-86, etc. to prevent any future bottle necks for all of these promising radioactive materials.